Dingke Medical Secures RMB 60 Million Series B Financing Led by Qiming Venture Partners

Med ValleyLatest News: DK Medtech Announces Completion of RMB 60 Million Series B Financing on October 8DK Medtech announced today (October 8) the completion of its RMB 60 million Series B financing round, led by Qiming Venture Partners with co-investment from Heyu No. 1 Fund. In October last year, DK Medtech secured a RMB 20 million Series A round exclusively invested by Yuanhe Origin. The proceeds from this round will be used to advance clinical trials and regulatory registration of cardiovascular interventional consumables, expand the R&D pipeline for other vascular intervention products, and gradually build up its commercial team.

According to public information, DK Medtech was established in July 2015 as a high-tech company specializing in the research, development, and manufacturing of vascular interventional medical devices. The company has currently completed registration testing and animal studies for several Class III medical devices. Notably, the pre-market clinical trials for its proprietary PCT-patented coronary drug-coated balloon (DCB), DissolveTM, have been initiated under the leadership of Fuwai Hospital and Anzhen Hospital. Multiple high-potential products representing the future direction of interventional therapy are currently under development, as the company strives to become a platform enterprise for interventional consumables in China.

DK Medtech founder Weng Yulin, formerly a key technical expert at Biosensors International (Singapore), has launched multiple star products in Europe, Japan, and China, contributing to the development of domestically produced alternatives.Medical DevicesWeng Yulin stated that, from the perspective of medical insurance cost control, domestic substitution is a trend. Moreover, in theory, DK Medtech is poised to outperform foreign medical enterprises. While foreign companies pioneered the initial innovations (from 0 to 1), DK Medtech has built upon overseas samples and data, gaining a deep understanding of the needs of the Chinese market, physicians, and patients to implement improvements that enhance performance and user experience.

Meanwhile, Weng Yulin specifically pointed out that unlike other companies that develop and launch products one by one, DK Medtech prefers to build a complete product portfolio from the outset. After obtaining regulatory approval for their smaller, non-clinical products, they refined their commercial operations and mass production capabilities. This strategy allowed for smoother market coverage when their core products were launched around 2020.

Regarding the investment in DK Medtech, Hu Xubo, Managing Partner at Qiming Venture Partners, stated: “The founding team of DK Medtech possesses many years of industry experience in cardiovascular devices, with successful international track records in developing interventional products and a deep understanding of the domestic clinical market. We are highly optimistic about DK Medtech and will support its development into a boutique company specializing in high-value consumables for vascular intervention.”